摘要
目的系统评价沙利度胺治疗艾滋病相关性复发性阿弗他溃疡(RAU)的疗效及安全性。方法明确探究沙利度胺治疗艾滋病相关性RAU的研究问题后,电子检索Cochrane图书馆临床对照试验库、Medline、荷兰医学文摘、中国生物医学文献数据库、中国期刊全文数据库和中文科技期刊数据库,检索日期截止于2011年9月。2位评价者独立使用Cochrane协作网推荐的标准对纳入文献进行偏倚风险评价并提取数据,采用RevMan5.0软件对符合纳入标准的文献进行分析。结果最终纳入研究的文献共2篇,Meta分析结果显示:沙利度胺组完全治愈率明显高于安慰剂组,其差异具有统计学意义;在不良反应方面,沙利度胺组皮疹和嗜睡的发生率高于安慰剂组,差异具有统计学意义,周围神经病变的发生率在两组间的差异无统计学意义。结论沙利度胺治疗艾滋病相关性RAU优于安慰剂组,但同时也增加了不良反应的发生率,但还需高质量、大样本、多中心的随机对照试验来提供更高级别的证据。
Objective To assess the efficacy and safety of thalidomide in patients with acquired immune defi- ciency syndrome （AIDS）-related recurrent aphthous ulcer（RAU）. Methods After identifying the study question of the efficacy and safety of thalidomide in patients with AIDS-related RAU, we searched Cochrane Controlled Trials Register, Medline, EMBASE, CBM, CNKI, VIP till September 2011. Risk of bias assessment with Cochrane Col- laboration＇s tool, and data extraction of included studies were conducted by two reviewers in duplicate. The soft- ware RevMan 5.0 was used for analysis. Results Two randomized controlled trials were included. Meta-analysis showed： The rate of complete healing of ulcers in thalidomide group was significantly higher than the placebo group, and the difference was statistically significant; In adverse reactions, the incidence of rash and somnolence in thalidomide group was higher than the placebo group, but there was no difference of peripheral sensory neu- ropathy in both groups. Conclusion Thalidomide treatment of AIDS-related RAU was superior to placebo, in the meantime increased the incidence of adverse reactions. Further high-quality and large-scale as well as multicenter randomized controlled trials are still needed to evaluate the efficacy and safety of thalidomide in patients with AIDS-related RAU.
出处
《国际口腔医学杂志》
CAS
2012年第5期572-574,共3页
International Journal of Stomatology
基金
教育部全国优秀博士学位论文作者专项基金资助项目(122030)
教育部霍英东基金高等院校青年教师基金资助项目(201080)
关键词
沙利度胺
艾滋病
复发性阿弗他溃疡
META分析
thalidomide
acquired immune deficiency syndrome： recurrent aphthous ulcer
Meta-analysis
